Mirum Pharmaceuticals (NASDAQ:MIRM) reported quarterly losses of $(0.30) per share which beat the analyst consensus estimate of $(0.44) by 31.82 percent. The company reported quarterly sales of $90.30 million which beat the analyst consensus estimate of $82.02 million by 10.10 percent. This is a 89.21 percent increase over sales of $47.73 million the same period last year.